ArticleJCO oncology practice2026
Longitudinal Associations Between Financial Toxicity and Health-Related Quality of Life for Patients With Cancer.
Article in JCO oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prevalence and Risk Factors for Financial Toxicity Among Sarcoma Patients During and Following Treatment Across the Lifespan.Cancer reports (Hoboken, N.J.) · 2026Article
- Understanding financial toxicity in cancer care through a social-ecological lens.Current opinion in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeEvaluate the longitudinal relationship between financial toxicity (FT), health-related quality of life (HR-QOL), and psychological distress for patients with cancer.
methodsAdults with cancer applying for foundation financial assistance or receiving treatment participated in a longitudinal survey study at any point in their cancer journey and 1, 3, and 6 months later. Validated surveys measured FT (Comprehensive Score for FT [COST]), HR-QOL (Functional Assessment of Cancer Therapy-General [FACT-G]), and psychological distress (Brief-Profile of Mood States [Brief-POMS]). Multilevel ordinal logistic and linear regression models assessed longitudinal relationships.
resultsOut of 1,112 approached, 732 (66%) completed the enrollment survey with subsequent response rates of 66%, 58%, and 52% at 1, 3, and 6 months, respectively. Participants had a mean age of 68 years. Most were non-Hispanic White (86%), male (57%), Medicare beneficiaries (82%), and had hematologic malignancies (53%). Most common cancer types were multiple myeloma and prostate cancer. Most (80%) had FT at enrollment (grade 1+ or COST <26), and FT was higher in earlier calendar months. Access to a financial counselor was associated with lower FT for those who desired a referral (adjusted odds ratio [aOR], 0.18). Previous (OR, 1.58) and current (OR, 1.73) intravenous chemotherapy were associated with higher FT. In multivariable multilevel models clustered by participants, higher FT was significantly associated with lower HR-QOL and greater psychological distress. The probability of any FT decreased from 79% at enrollment to 72% at 1 month and 68% at 3 and 6 months.
conclusionPatients with various cancer types had associations between higher FT, lower HR-QOL, and more psychological distress across repeated measures over 6-month intervals. FT screening should be repeated across the cancer care continuum, especially early in the calendar year. This will allow interventions to improve patients' emotional and physical well-being.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.